CMCara McKenna

Cara McKenna

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cara McKenna has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Tailored care for patients with possible pneumonia who test positive for viruses

    by Brett Biebelberg, Tom Chen, Cara McKenna, Sanjat Kanjilal, Claire Shappell, Chanu Rhee, Michael Klompas

  • Associations between antibiotic use and outcomes in patients hospitalized with community-acquired pneumonia and positive respiratory viral assays

    by Brett Biebelberg, Tom Chen, Cara McKenna, Sanjat Kanjilal, Claire Shappell, Chanu Rhee, Michael Klompas

    Background: Newly released community-acquired pneumonia (CAP) guidelines include a conditional recommendation to treat all hospitalized patients with positive respiratory virus assays with antibacterials. We assessed the frequency, duration, and outcomes of antibacterial prescribing in this population. Methods: We retrospectively identified all hospitalized patients with possible CAP and a positive respiratory virus test at five hospitals, June 2015-December 2024. We used detailed clinical data to propensity-weight patients treated with 0-2 vs 5-7 days of antibacterials and compared outcomes overall and for different viruses. Results: Among 6779 patients with possible CAP and a respiratory virus, 3269 were treated with 0-2 days and 1560 with 5-7 days of antibacterials. After propensity-weighting 2614 patients (1720 treated 0-2 days, 894 treated 5-7 days), there were no significant differences in hospital length of stay (11.7 days vs 11.1 days; OR 1.05, 95% CI 0.97-1.15), ICU admission after 48 hours (28.3% vs 28.2%; OR 1.01, 95% CI 0.86-1.18), in-hospital mortality (9.5% vs 9.8%; OR 0.97, 95% CI 0.74-1.27), or 30-day hospital-free days (16.9 days vs 17.0 days; OR 0.99, 95% CI 0.95-1.03). Results were consistent when restricted to non-SARS-CoV-2 viruses and to influenza alone, when comparing 0 vs 5-7 days of antibacterials, and when restricting to patients with ICD-10 codes for pneumonia present on admission. Conclusions: Antibacterial use for patients with possible CAP and respiratory viruses is highly variable but outcomes are similar with 0-2 vs 5-7 days of antibacterials. This suggests antibiotics are not beneficial in most CAP patients who test positive for respiratory viruses.


  • Morbidity and Mortality of Hospital-Onset SARS-CoV-2 Infections Due to Omicron Versus Prior Variants

    by Michael Klompas, Caroline S. McKenna, Sanjat Kanjilal, Theodore Pak, Chanu Rhee, Tom Chen

    Many hospitals have scaled back measures to prevent nosocomial SARS-CoV-2 infection given large decreases in the morbidity and mortality of SARS-CoV-2 infections for most people. Little is known, however, about the morbidity and mortality of nosocomial SARS-CoV-2 infections for hospitalized patients in the Omicron era. To estimate the effect of nosocomial SARS-CoV-2 infection on hospitalized patients' outcomes during the pre-Omicron and Omicron periods. Retrospective matched cohort study. 5 acute care hospitals in Massachusetts, December 2020 to April 2023. Adults testing positive for SARS-CoV-2 on or after hospital day 5, after negative SARS-CoV-2 test results on admission and on hospital day 3, were matched to control participants by hospital, service, time period, days since admission, and propensity scores that incorporated demographics, comorbid conditions, vaccination status, primary diagnosis category, vital signs, and laboratory test values. Primary outcomes were hospital mortality and time to discharge. Secondary outcomes were intensive care unit (ICU) admission, need for advanced oxygen support, discharge destination, hospital-free days, and 30-day readmissions. There were 274 cases of hospital-onset SARS-CoV-2 infection during the pre-Omicron period and 1037 cases during the Omicron period (0.17 vs. 0.49 cases per 100 admissions). Patients with hospital-onset SARS-CoV-2 infection were older and had more comorbid conditions than those without. During the pre-Omicron period, hospital-onset SARS-CoV-2 infection was associated with increased risk for ICU admission, increased need for high-flow oxygen, longer time to discharge (median difference, 4.7 days [95% CI, 2.9 to 6.6 days]), and higher mortality (risk ratio, 2.0 [CI, 1.1 to 3.8]) versus matched control participants. During the Omicron period, hospital-onset SARS-CoV-2 infection remained associated with increased risk for ICU admission and increased time to discharge (median difference, 4.2 days [CI, 3.6 to 5.0 days]). The association with increased hospital mortality was attenuated but still significant (risk ratio, 1.6 [CI, 1.2 to 2.3]). Residual confounding may be present. Hospital-onset SARS-CoV-2 infection during the Omicron period remains associated with increased morbidity and mortality. Harvard Medical School Department of Population Medicine.


  • Heterogeneity of Sepsis Presentations and Mortality Rates

    by Brett Biebelberg, Chanu Rhee, Tom Chen, Caroline McKenna, Michael Klompas


  • Open Access

    Surveillance and Outcomes for Non-Ventilator Hospital-Acquired Pneumonia Events Using Structured Electronic Clinical Data

    by S. Stern, M. Nevers, Y. Jian, M.A. Christensen, A. Ochoa, C. Rhee, R. Jin, C. McKenna, R. Poland, J. Guy, et al.